Atomo Diagnostics Ltd (ASX: AT1) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Atomo Diagnostics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $12.14 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 639.20 million
Earnings per share -0.011
Dividend per share N/A
Year To Date Return -13.64%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Atomo Diagnostics Ltd (ASX: AT1)
    Latest News

    Healthcare Shares

    Atomo Diagnostics share price charges higher on expanded COVID-19 testing partnership

    The Atomo Diagnostics Ltd (ASX: AT1) share price is charging higher this morning on the back of a COVID-19 testing…

    Read more »

    AT1 ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Atomo Diagnostics Ltd

    Atomo Diagnostics Limited is a medical device company. Its Rapid Diagnostic Test devices are used both by healthcare professionals and by consumers to screen for a range of diseases and medical conditions

    AT1 Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    22 Nov 2024 $0.02 $0.00 0.00% 466,736 $0.02 $0.02 $0.02
    19 Nov 2024 $0.02 $0.00 0.00% 22,336 $0.02 $0.02 $0.02
    18 Nov 2024 $0.02 $0.00 0.00% 398,321 $0.02 $0.02 $0.02
    15 Nov 2024 $0.02 $0.00 0.00% 394,572 $0.02 $0.02 $0.02
    14 Nov 2024 $0.02 $0.00 0.00% 46,395 $0.02 $0.02 $0.02
    13 Nov 2024 $0.02 $0.00 0.00% 1,041,676 $0.02 $0.03 $0.02
    12 Nov 2024 $0.02 $0.00 0.00% 2,000 $0.02 $0.02 $0.02
    11 Nov 2024 $0.02 $0.00 0.00% 89,199 $0.02 $0.02 $0.02
    08 Nov 2024 $0.02 $0.00 0.00% 200,374 $0.02 $0.02 $0.02
    07 Nov 2024 $0.02 $0.00 0.00% 4,000 $0.02 $0.02 $0.02
    06 Nov 2024 $0.02 $0.00 0.00% 354,390 $0.02 $0.02 $0.02
    05 Nov 2024 $0.02 $0.00 0.00% 63,000 $0.02 $0.02 $0.02
    04 Nov 2024 $0.02 $0.00 0.00% 479,668 $0.02 $0.02 $0.02
    01 Nov 2024 $0.02 $0.00 0.00% 206,075 $0.02 $0.02 $0.02
    31 Oct 2024 $0.02 $0.00 0.00% 5,439 $0.02 $0.02 $0.02
    30 Oct 2024 $0.02 $0.00 0.00% 325,521 $0.02 $0.02 $0.02
    29 Oct 2024 $0.02 $0.00 0.00% 1,392,852 $0.02 $0.02 $0.02
    28 Oct 2024 $0.02 $0.00 0.00% 419,000 $0.02 $0.02 $0.02

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Paul Alexander Kasian Non-Executive Director
    Dr Kasian is an executive director with demonstrated achievement in both domestic and international companies encompassing senior leadership, strategy, investment and risk roles. His other roles have included Chief Investment Officer and Head of Global Financials at HSBC Asset Management, Founding Director of Accordius and Founding Director of Wallara Asset Management. He is also Chair of Risk Committee and member of the People and Culture Committee.
    Mr John Perry Keith Non-Executive ChairmanNon-Executive Director Dec 2011
    Mr Keith is one of the Managing Directors at BNP Paribas, establishing and leading its financial institutions coverage team. Prior to joining BNP Paribas in 2011, Mr Keith held country management and senior business and coverage positions for Nomura Securities in Sydney and Hong Kong. His career comprises working with supranational, sovereign, and institutional clients across all areas of investment and institutional banking. He is Member of the Risk Committee and member of the People and Culture Committee.
    Mr John Michael Kelly FounderChief Executive OfficerManaging Director Apr 2010
    Mr Kelly has focused on developing and commercializing innovative healthcare products that enhance usability and performance, having started with CR Bard in Europe developing Class III implantable cardiology products. Prior to joining Unilife in 2005, Mr Kelly spent five years at ResMed where he led the New Product Implementation Group and managed the development of the Mirage Swift and Activa mask systems.
    Ms Deborah Neff Non-Executive Director Sep 2021
    Ms Neff has spent most of her career building global businesses. As principal of DJN Consulting, LLC based in the San Francisco Bay Area, Deborah currently works with several privately held healthcare start-up companies providing strategic business advice and mentoring to the executive management teams. Previously was CEO of Evanostics, LLC, Pathwork Diagnostics Inc, and COO at Complete Genomics following a 15-year career with Becton Dickinson, where she last served as President of BD Biosciences, a global business unit of the company. She is an Executive Trustee of the University of California, Davis Foundation and chairs the College of Biological Sciences Leadership Council at the University. He is also member of the Risk Committee.
    Dr Cheri Louise Walker Non-Executive Director Nov 2022
    Dr Walker is an executive with more than twenty-five years of experience working with life science and diagnostic companies. Dr. Walker is currently the President, Chief Executive Officer, and Director of Rhinostics. She has previously held senior executive positions at Abcam; Charles River Labs; Qiagen, and Life Technologies, now part of ThermoFisher. He is a member of the Risk Committee.
    Mr Mathew Leslie Watkins Company Secretary Jun 2024
    -
    Mathew Leslie Watkins Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    GZ Family Holdings Pty Ltd 79,787,536 12.48%
    Dalraida Holdings Pty Limited 65,120,000 10.19%
    Global Health Investment Fund 64,811,280 10.14%
    Mr Xiaoyi Lin 11,880,000 1.86%
    Grand Challenges Canada 11,390,824 1.78%
    Liverbird Pty Ltd 10,931,653 1.71%
    Australia West Holdings Pty 10,500,000 1.64%
    Australia North Holdings Pty 9,580,000 1.50%
    ID&E Pty Ltd 9,032,248 1.41%
    Mark Andrew Smith 7,790,224 1.22%
    Mr Ian Fredrick Johnson 7,506,080 1.17%
    John Michael Kelly 7,370,248 1.15%
    Leo James Lynch 7,321,121 1.15%
    Citicorp Nominees Pty Limited 6,355,684 0.99%
    Mr Ankur Choudhary 5,887,126 0.92%
    Ruth Karen Devney 5,626,408 0.88%
    Sokolov Pty Ltd 4,031,888 0.63%
    H & L Management Pty Ltd 4,000,000 0.63%
    Rue Des Rocs Pty Ltd 3,800,000 0.59%
    Miss Lisa Marie Mackenzie 3,351,968 0.52%

    Profile

    since

    Note